GlassScriptPhysician profile
Neel Patel
NPI 1801250766
$3,470.02
in general payments reported to CMS, 2019-2025
19 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.19 · 2021: $96.53 · 2022: $278 · 2023: $2,016 · 2024: $262 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,599 · Food and Beverage: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,598.51 |
| Food and Beverage | $1,476.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apollo Endosurgery US INC | $1,018.59 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Medical Device Business Services, INC. | $977.52 | 2023 | Dynacord |
| Abbvie INC. | $406.66 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.39 | 2023-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $164.90 | 2025 | Rezdiffra |
| Ardelyx, INC. | $133.57 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $50.22 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $47.84 | 2022-2024 | Sucraid |
| Ironwood Pharmaceuticals, INC | $37.59 | 2024 | |
| Genzyme Corporation | $28.49 | 2025 | |
| Mallinckrodt Hospital Products INC. | $24.44 | 2023 | Terlivaz |
| Endogastric Solutions, INC | $23.12 | 2024 | Esophyx |
| Boston Scientific Corporation | $20.30 | 2022 | |
| Celgene Corporation | $17.04 | 2022 | |
| Ge Healthcare | $16.82 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $16.32 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $14.78 | 2025 | Suflave, Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $14.65 | 2023 | Entyvio |
| Phathom Pharmaceuticals, INC. | $12.53 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neel Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.